Patent 12447128
PTAB challenges
AIA trial proceedings at the USPTO Patent Trial and Appeal Board — IPR, PGR, and CBM. Petitioners, judge panels, claim-level invalidation outcomes from Final Written Decisions, and Federal Circuit appeals. The single most important defensive datapoint after litigation history.
Active provider: Google · gemini-2.5-flash
Proceedings on file (0)
All PTAB activity →AIA trial proceedings (IPR / PGR / CBM) filed at the USPTO Patent Trial and Appeal Board against this patent. Sourced from the USPTO Open Data Portal and refreshed every six hours; each proceeding number deep-links to the PTAB E2E docket.
Current assignee: Astellas US LLC, Medivation AG, Astellas Pharma Inc, Medivation Prostate Therapeutics LLC
No PTAB proceedings on file. This patent has not been challenged via IPR, PGR, or CBM. The absence is itself a signal — well-asserted patents eventually attract IPRs. The LLM analysis below may surface filings the ODP feed hasn’t indexed yet.
PTAB challenges
AIA trial proceedings at the USPTO Patent Trial and Appeal Board — IPR, PGR, and CBM. Petitioners, judge panels, claim-level invalidation outcomes from Final Written Decisions, and Federal Circuit appeals. The single most important defensive datapoint after litigation history.
Proceedings overview
There is no PTAB activity on file for US patent 12447128. This suggests that the patent has not yet been challenged in an AIA trial proceeding, which could indicate a less hardened defensive posture if faced with assertion.
Strategic summary
As there are no PTAB proceedings on file for US patent 12447128, all claims of the patent remain untested by AIA trial proceedings. This means there are no canceled or sustained claims through IPR, PGR, or CBM. Consequently, there is no estoppel landscape established by the PTAB regarding this patent, and all prior-art grounds remain available for potential challenges. The absence of PTAB activity also means there are no patterns to observe regarding petitioner behavior, patent owner's appeal aggressiveness, or involvement of defensive aggregators like Unified Patents.
Recommended next steps
If you are a defendant facing assertion of US patent 12447128, the absence of PTAB activity means that all claims are currently presumed valid from an AIA trial perspective. An IPR, PGR, or CBM could be considered as a defense strategy, as the patent has not yet undergone the scrutiny of these proceedings.
Generated 5/31/2026, 6:45:51 AM